expressed in ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), pentet (p), multiplet (m), broad (br), or a combination thereof. Coupling constants (J) are quoted to the nearest 0.1 Hz.
LC-MS analyses were performed with either an Agilent HPLC 1100 series connected to a Bruker Daltonics MicrOTOF, or an Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 quadrupole LC-MS, where both instruments were connected to an Agilent diode array detector. LC-MS chromatographic separations were conducted with a Waters Xbridge C18 column, 50 mm x 2.1 mm, 3.5 μm particle size; mobile phase, water/acetonitrile +0.1% HCOOH, or water/acetonitrile + 0.1% NH 3 ; linear gradient 80:20 to 5:95 over 3.5 min, and then held for 1.5 min; flow rate 0.5 mL min -1 . All assay compounds had a measured purity of ≥95% (by TIC and UV) as determined using this analytical LC-MS system. High resolution electrospray measurements were performed on a Bruker Daltonics MicrOTOF mass spectrometer. Microwave-assisted chemistry was performed using a Biotage Initiator Microwave Synthesizer.
Compounds 25, 26, 33 and 34 were purchased from Enamine as solids. Purity (>97%) and molecular mass were confirmed by HPLC high resolution mass spectrometry. N-(1-Isopropyl-3,5-dimethyl-1H-pyrazol-4-yl) -4-methoxy-2,3,6-trimethylbenzenesulfonamide (4).
Prepared from N- (3,5-dimethyl-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide 2 (100 mg, 0.31 mmol), cesium carbonate (202 mg, 0.62 mmol) and 2-bromopropane (76 mg, 0.62 mmol) in DMF (5 ml) according to the method of 3 to give the title compound as an off-white solid (21 mg, 0.057 mmol, 19%) . 1 H NMR (500MHz, DMSO-d 6 ):  8.34 (s, 1H), 6.38 (s, 1H) , 4.80 (p, J = 6.8 Hz, 1H), 3.73 (s, 3H) , 2.55 (s, 3H), 2.36 (s, 3H), 2.16 (s, 3H), 2.04 (s, 3H), 1.83 (s, 3H), 1.10 (d, J = 6.8 Hz, 6H) . HRMS (m/z): [MH + ] calcd for C 18 H 28 N 3 SO 3 , 366.1846; found 366.1848 .
N-(1,3-Dimethyl-5-morpholino-1H-pyrazol-4-yl)-4-methoxy-2,3,6-trimethylbenzene sulfonamide (5).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (317mg, 1.27mmol) and 1,3dimethyl-5-morpholino-1H-pyrazol-4-amine (250 mg, 1.27 mmol) in pyridine (3.0 ml) according to the method of 1, to give the title compound as an off-white solid (320 mg, 0.78 mmol, 62% 4 , 409.1904; found 409.1911 .
4-Methoxy-2,3,6-trimethyl-N-(1H-pyrazol-3-yl)benzenesulfonamide (6).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (100 mg, 0.4 mmol) and 1Hpyrazol-3-amine (33 mg, 0.4 mmol) in pyridine (3.0 ml) according to the method of 1, to give the title compound as an off-white solid (23 mg, 0.078 mmol, 19% 
N-(Imidazo[1,2-a]pyridin-3-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide (7).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and imidazo[1,2-a]pyridin-3-amine (133 mg, 1.0 mmol) in pyridine (10.0 ml) 
4-Methoxy-2,3,6-trimethyl-N-(pyridin-3-yl)benzenesulfonamide (8).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and 3aminopyridine (94 mg, 1.0 mmol) in pyridine (4.0 ml) according to the method of 1, to give the title compound as an off-white solid (117 mg, 0.38 mmol, 38% 
4-Methoxy-2,3,6-trimethyl-N-(2-methylpyridin-3-yl)benzenesulfonamide (9).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and 2methyl-3-aminopyridine (107 mg, 1.0 mmol) in pyridine (4.0 ml) according to the method of 1, to give the title compound as an off-white solid (110 mg, 0.34 mmol, 34% 
N-(3,5-Dimethylisoxazol-4-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide (10).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and 3,5dimethylisoxazol-4-amine (112 mg, 1.0 mmol) in pyridine (4.0 ml) according to the method of 1, to give the title compound as an off-white solid (212 mg, 0.65 mmol, 65% 
N-(3,4-Dimethylisoxazol-5-yl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide (11).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and 3,4dimethylisoxazol-5-amine (112 mg, 1.0 mmol) in pyridine (4.0 ml) according to the method of 1, to give the title compound as white solid (72 mg, 0.22 mmol, 22% 
4-Methoxy-2,3,6-trimethyl-N-phenylbenzenesulfonamide (12).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and aniline (93 mg, 1.0 mmol) in pyridine (3.0 ml) according to the method of 1, to give the title compound as white solid (212 mg, 0.69 mmol, 69%). 1 H NMR (500MHz, DMSO-d 6 ):  10.15 (s, 1H), 7.19 (t, J = Supporting Information 6 7.5 Hz, 2H), 6.98-6.94 (m, 3H), 6.78 (s, 1H) NSO 3 , 306.1158; found 306.1144 .
N-Benzyl-4-methoxy-2,3,6-trimethylbenzenesulfonamide (13).
Prepared from 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (248 mg, 1.0 mmol) and benzylamine (107 mg, 1.0 mmol) in pyridine (3. 
4-Bromo-N-isobutyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzamide (18).
Isobutyraldehyde (73 L, 0.8 mmol) was added to an ice-cooled mixture of 1,3,5-trimethyl-1Hpyrazol-4-amine (100 mg, 0.8 mmol), acetic acid (137 l, 2.4 mmol) and NaBH(OAc) 3 (424 mg, 2.0 mmol) in anhydrous DCM (10.0 mL). The reaction mixture was allowed to warm to rt and stirred for 6 h. The reaction was diluted with DCM (50 ml), washed with water, the organic layer separated and concentrated in vacuo. Chromatography (SiO 2 , EtOAc) gave N-isobutyl-1,3,5trimethyl-1H-pyrazol-4-amine as a low-melting white solid (92 mg, 0.51 mmol, 64 %). 4-Bromobenzoylchloride (90 mg, 0.41 mmol) was added to a solution of N-isobutyl-1,3,5-trimethyl-1H-pyrazol-4-amine (74 mg, 0.41 mmol) in DCM (5.0 mL) and pyridine (1.0 ml). The reaction mixture was stirred at rt for 5 h, concentrated in vacuo and purified by column chromatography (SiO 2 , 1:1 EtOAc:Hexanes) to give the title compound (55 mg, 0.15 mmol, 37%). 1 A stirred solution of (1,3,5-trimethyl-1H-pyrazol-4-yl)methanol (1.4 g, 10.0 mmol) in chloroform (20.0 ml) at rt was treated dropwise with thionyl chloride (2.9 mL, 40.0 mmol). The reaction was then heated to reflux for 1.5 h. Concentration to dryness in vacuo gave 4-(chloromethyl)-1,3,5trimethyl-1H-pyrazole hydrochloride as a fine white powder (2.8 g, 10.0 mmol, 99%). 4-Bromobenzenesulfonyl chloride (5.0 g, 19.6 mmol) was added portionwise to a stirred solution of potassium phosphate (2.67 g, 19.6 mmol) and sodium sulfite (4.94 g, 39.2 mmol) in water (60.0 ml) at 30°C. The reaction was then heated to 60°C for 18 h. The reaction was concentrated to dryness in vacuo to give crude sulfinate salt. This material was then added portionwise to a solution of 4-(chloromethyl)-1,3,5-trimethyl-1H-pyrazole hydrochloride (559 mg, 2.0 mmol) in acetone (8.0 mL) and water (5 ml) and heated to 60°C for 2 h. 
N-(4-Bromobenzyl)-1,3,5-trimethyl-1H-pyrazol-4-amine (21).
A solution of 4-bromobenzyl bromide (502 mg, 2.01 mmol), potassium carbonate (600 mg, 4.3 mmol), potassium iodide (200 mg, 1.2 mmol) and 1,3,5-trimethyl-1H-4-aminopyrazole (256 mg, 2.04 mmol) in DMF (10.0 ml) was heated at 80ºC for 16 h. The reaction was concentrated in vacuo, diluted with water (5 ml) and stirred for a further 1 h at rt prior to extraction with EtOAc (3 x 25 ml). The extracts were washed with brine, dried (MgSO 4 ) and concentrated in vacuo. A solution of 4-bromophenol (482 mg, 2.79 mmol) and (1,3,5-trimethyl-1H-pyrazol-4-yl)methanol (585 mg, 4.18 mmol) in THF (15.0 ml) was treated with polymer-supported triphenylphosphine (polystyrene, 2.2 mmol/g, 1.9 g, 4.18 mmol) followed by diisopropylazodicarboxylate (844 l, 4.18 mmol) and heated to 70ºC for 5 h, prior to concentration in vacuo. Chromatography (SiO 2 , 4:1 hexanes:EtOAc) gave the title compound as a white solid (474 mg, 1.6 mmol, 58%). 1 N-(4-Bromophenyl)-1,3,5-trimethyl-1H-pyrazole-4-carboxamide (24) . Bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide (29) . 
4-

6-Morpholino-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide (31).
Prepared from 6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide 37 (150 mg, 0.5 mmol) and morpholine (0.25 ml) in ethanol (2.0 ml), according to the method of 42 to give the title compound as a pale yellow powder (112 mg, 0.32 mmol, 64%). 1 H NMR (500MHz, DMSO- 
4-(2-Methylthiazol-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide (32).
Prepared from 4-(2-methylthiazol-4-yl)benzene-1-sulfonyl chloride (249 mg, 1.0 mmol) and 4amino-1,3,5-trimethyl-1H-pyrazole (125 mg, 1.0 mmol) in pyridine (3.0 ml) according to the method of 1, to give the title compound as an off-white solid (247 mg, 0.68 mmol, 68%). 1 H NMR N-(4-(N-(1,3,5-Trimethyl-1H-pyrazol-4-yl) 
3',5'-Dichloro-4'-(N-(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl)-[1,1'-biphenyl]-3carboxamide (36).
Prepared from 4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide (29) (250 mg, 0.61 mmol), (3-carbamoylphenyl) 
6-Chloro-pyridine-3-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)-amide (37).
Prepared from 6-chloropyridine-3-sulfonyl chloride (4.8 g, 22.7 mmol) and 4-amino-1,3,5trimethyl-1H-pyrazole (2.84 g, 22.7 mmol) in pyridine (35.0 ml) according to the method of 1, to give the title compound as an off-white solid (5.13 g, 17.1 mmol, 75%). 1 Prototypical procedure for preparation of a 2-aminopyridine by displacement reaction of a 2chloropyridine with an alkylamine (thermal conditions): (1,3,5-trimethyl-1H- pyrazol-4-yl)-amide (42). 3, pyridine-3-sulfonamide (37) (225 mg, 0.75 mmol) and 4-(2-aminoethyl)-methylpiperazine (215 mg, 1.5 mmol) in ethanol (2.0 ml), was heated at N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide (38) . Hz, 1H), 6.58-6.54 (m, 1H), 6.38-6.36 (m, 1H) , 4.59 (s, 2H), 3.53 (s, 3H), 1.85 (s, 3H), 1.66 (s, 3H). 4-((Dimethylamino)methyl)benzyl)(methyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4- 
6-[2-(4-Methyl-piperazin-1-yl)-ethylamino]-pyridine-3-sulfonic acid
6-(Benzylamino)-
6-((
yl)pyridine-3-sulfonamide (40).
Prepared from 6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridine-3-sulfonamide (37) (250 mg, 0.83 mmol) and N,N-dimethyl-1-(4-((methylamino)methyl)phenyl)methanamine (560 mg, 2.23 mmol) in ethanol (1.5 ml), according to the method of 42, to give the title compound as an off-white powder (216 mg, 0.49 mmol, 59%). 1 6-((2-Morpholinoethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl) ((2-(Piperazin-1-yl)ethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl) 6-((2-(Piperidin-1-yl)ethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl) ((2-(4-Isopropylpiperazin-1-yl)ethyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl) 5-(N-(1,3 ,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl)pyridin-2yl)amino)ethyl)piperazine-1-carboxylate (54).
6-
Prepared from 6-chloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl) -((4-methylpiperazin-1-yl)methyl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-[1,1'- 
biphenyl]-4-sulfonamide (57).
Prepared from 4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide (29) ( 6-Dichloro-4-(2-piperazin-1-yl-pyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4- 3, 143.8, 137.4, 136.3, 135.2, 129.8, 111.8, 111.7, 109.1, 108.9, 42.7, 42.0, 36.2, 10.4 . HRMS (m/z): [MH + ] calcd for C 21 H 25 N 6 SO 2 Cl 2 , 495.1131; found 495.1124. Values between brackets for the highest resolution shell. a Rmerge = ∑|I -<I>| / ∑<I>. b R-factor = ∑F o -F c | / ∑ F o . c Number of atoms of protein, co-factor, ligand and water molecules respectively. 
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